Big Shot: Developments in Prefilled Syringes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Shot: Developments in Prefilled Syringes
Many companies are coming up with innovative materials and manufacturing methods to feed the growing demand for prefilled syringes.


Pharmaceutical Technology




Like all consumers, patients and healthcare providers want products that will make their lives easier, and any product that makes administering or taking an injection easier is bound to be popular. It's no wonder, then, that the vast majority of pharmaceutical companies are noting the advantages of prefilled syringes and scrambling to include them in their portfolios.

Prefilled syringes are not a new technology by any means. They debuted during World War II to accommodate the need for on-the-spot, sterile medications in battlefield hospitals. The next big push into the market came when Becton Dickinson and Company (BD, Franklin Lakes, NJ) began supplying glass prefillable syringes to support Dr. Jonas Salks' poliomyelitis vaccination program in the early 1950s. Prefilled syringes continued to be used mostly for delivering insulin or human growth hormone. In the past five years, however, they have really come into their own, becoming not just a desirable product but almost a required product for parenteral makers to offer.

"If you're going to launch a new product with an already competitive indication, it should be filled in a prefilled syringe for success on the market," says Jörg Zimmermann, head of production at Vetter Pharma-Fertigung GmbH & Co. "Most innovative new products, if they're liquid, are going to be in a syringe, when appropriate."

The numbers attest to this: a study conducted by BD and IMS Health shows that the market for prefilled syringes is expected to grow by 12.8% per year. In 2006, about 1.4 billion prefilled syringes were sold, and by 2010 the quantity is expected to top 2.4 billion.

Changes drive increasing interest

The sudden and intense interest in prefilled syringes can be attributed to several changes in the industry.

Ease of use. The market has seen an increase in the number of biotechnology therapies and drug candidates that can only be administered by injection. These new treatments target a wide range of areas such as multiple sclerosis, fertility, osteoperosis, hepatitis, rheumatoid arthritis, cancer, anemia, and hemophilia.

Some biotech-based drugs require frequent injections to be administered by the patients themselves, and it's these patients, according to Michael N. Eakins, principal consultant with Eakins & Associates (West Windsor, NJ), who stand to benefit the most from the ease of use a prefilled syringe offers.

"A prefilled syringe takes out a series of operations, which makes it quicker and easier," notes Eakins. "It's a great advantage from the patient point of view in ease, safety, and training to have a dose all ready to go in a prefilled syringe."

It's patients who are the true driving force behind the demand for prefilled syringes. Measuring out a dose from a vial into a syringe may be time-consuming and pose a risk for error for those with little training. Moreover, diseases such as rheumatoid arthritis often make it difficult or even impossible for patients to hold a vial and withdraw an accurate dose. Pharmaceutical products that started out as a lyophilized formulations have been changed to liquid formulations to be packaged in prefilled syringes. Berlex's (Wayne, NJ) "Betaseron" multiple sclerosis treatment, and the human growth hormones "Norditropin" (Novo Nordisk, Princeton, NJ), and "Nutropin" (Genentech, San Francisco, CA) all have been reformulated from lyophilized to liquid and are now offered in prefilled syringes.

Ease of manufacture. Syringe component suppliers have stepped up to meet the rising demand in ready-to-use units. Stelmi's (Paris, France) ready-to-use plungers and BD's "Hypak SCF" prefillable syringes eliminate the need for washing, depyrogenation, and sterilization at the filling site. Ready-to-use components are washed, EtO or gamma sterilized, and validated for direct use.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here